Treatments

*April 2024* This is  a recorded event where a team of top oncologists discusses emerging concepts and best practices in non-small cell lung cancer (NSCLC). In this video, Dr. Lyudmila Bazhenova discusses toxicities associated with antibody-drug conjugate treatment. Watch video here.

*April 2024* Abstract Background Current standard of care treatment for patients with ≥15 brain metastases(BM) is whole brain radiation therapy(WBRT), despite poor neurocognitive outcomes. We analyzed our institutional experience of treating these patients with stereotactic radiosurgery(SRS), with the aim of evaluating safety, cognitive outcomes, and survival metrics. Methods Patients who…

*April 2024* Video: Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a…

*April 2024* “The rapidly evolving first-line treatment landscape for patients with metastatic EGFR mutant non-small cell lung cancer (NSCLC)” remains a “hot topic,” according to Eric K. Singhi, MD, assistant professor at the University of Texas MD Anderson Cancer Center. He and fellow “Leading Thoughts: Lung Cancer” panelists Maya Khalil, MD, thoracic…

*April 2024* Although the use of the tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) is the preferred frontline approach in patients with non-small cell lung cancer (NSCLC) with classic EGFR mutations, acquired resistance mechanisms invariably develop. “When we think about acquired resistance to TKIs, this is not limited to EGFR and ALK—it is a universal persistent…

*April 2024* Video: Dr. Joseph Treat from  Fox Chase Cancer Center discusses the LP-300 clinical trial regarding EGFR+ NSCLC in  the never smoker population. Watch video here.

*March 2024* In this podcast, Dr. Paul Wheatley-Price sits down with Dr. Amir Safavi, final-year Radiation Oncology Resident at the University of Toronto, and Dr. Jillian Tsai, Staff Radiation Oncologist at Princess Margaret Cancer Centre. They preface the chat with radiation 101, describe what "oligo-" means in the context of…

*March 2024* The phase 3 MARIPOSA trial (NCT04487080) evaluating a regimen of amivantamab-vmjw (Rybrevant) and lazertinib vs standard-of-care osimertinib (Tagrisso) for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) had promising results, showing the superiority of amivantamab/lazertinib over osimertinib. The combination demonstrated a longer progression-free survival (PFS) and duration…

*March 2024* Note to reader: Although Tagrisso is the preferred first-line treatment, some patients who took a 1st or 2nd generation drug as first-line (Tarceva, Afatinab) and then Tagrisso as second-line experienced a much longer PFS (progression-free survival) than those who started with Tagrisso. ABSTRACT Here, I suggest that while…

*March 2024* Abstract Introduction Characteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. Methods Clinical characteristics and outcomes were abstracted from the electronic…